Bondi made changes to DOJ policy. Her former client Pfizer might have benefited
By Ben Wieder
Updated July 6, 2025 3:58 PM
For the past several years, pharmaceutical giant Pfizer has been under investigation by the U.S. Department of Justice for potential foreign corruption violations related to its activities in China and Mexico, according to the company’s financial filings.
But that appears to have changed after the Trump administration tapped Pam Bondi — previously an outside legal counsel for Pfizer — to lead the Justice department as attorney general.
In the company’s most recent annual report, filed three weeks after Bondi took office in early February, there was no longer any reference to the Justice Department investigations into the company’s potential violation of the Foreign Corrupt Practice Act. A quarterly report in May also contains no reference to these investigations.
On her first day in office, Bondi rolled back the enforcement of foreign corruption cases that didn’t involve drug cartels and international criminal organizations, among a host of sweeping changes she made to the department’s priorities. That move was followed five days later, on Feb. 10, by a related executive order issued by President Donald Trump that paused new foreign corruption investigations and enforcement actions.
more
https://amp.miamiherald.com/news/politics-government/article309804745.html
